ArticleMolecular biology reports2026
Gypenosides mitigate acrylamide-induced oxidative stress, inflammation and lipid metabolic dysregulation in retinal pigment epithelial cells and in zebrafish embryos.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcrylamide (ACR) is an environmental and dietary contaminant widely known to induce imbalance in several biological systems, including oxidative stress, inflammation, and metabolic dysregulation. This study investigated the protective effects of gypenosides (GYP) against ACR-induced toxicity in human retinal pigment epithelial (RPE) cells and zebrafish embryos. METHODS AND
resultsRPE cells and zebrafish embryos were treated with ACR, or ACR + GYP; the levels of reactive oxygen species (ROS), antioxidative enzymes, proinflammatory cytokines, and lipids were measured using biochemical approaches. Our findings demonstrate that ACR exposure significantly elevated ROS production, increased lipid peroxidation, suppressed antioxidant defences, and upregulated pro-inflammatory cytokines in RPE cells. Additionally, ACR disrupted lipid metabolism, significantly increasing cellular cholesterol, triglyceride, and phospholipid levels while altering cholesterol metabolism gene expression. Co-treatment with GYP effectively mitigated ACR-induced oxidative stress by normalising ROS levels, restoring antioxidant enzyme activities, and upregulating antioxidant gene expression. GYP also attenuated the ACR-triggered inflammatory response, significantly downregulating the expression of proinflammatory cytokine genes. Furthermore, GYP normalised lipid profiles and modulated lipid-related gene expression disrupted by ACR exposure. Parallel zebrafish experiments corroborated these protective effects. ACR exposure led to delayed hatching, impaired cardiac function, increased ROS production, and neutral lipid accumulation. These adverse effects were markedly ameliorated by GYP co-treatment, which reduced oxidative stress, downregulated proinflammatory markers, and restored lipid homeostasis.
conclusionThe results highlighted that GYP, as a natural protective agent against ACR-induced cellular and metabolic toxicity in both in vitro and in vivo models, exhibited antioxidative, anti-inflammatory, and lipid-regulatory properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.